Back to Search
Start Over
Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.
- Source :
- Cancer Chemotherapy & Pharmacology; Dec2017, Vol. 80 Issue 6, p1073-1077, 5p
- Publication Year :
- 2017
- Subjects :
- CASTRATION-resistant prostate cancer
PROSTATE cancer patients
ANDROGEN receptors
Subjects
Details
- Language :
- English
- ISSN :
- 03445704
- Volume :
- 80
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- Cancer Chemotherapy & Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 126216042
- Full Text :
- https://doi.org/10.1007/s00280-017-3433-3